OCC
ORTHOCELL LIMITED ORDINARYOrthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
OCC
OCC
ORTHOCELL LIMITED ORDINARY
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 0.39% | — |
| 10 July | 0.38% | — |
| 9 July | 0.38% | — |
| 8 July | 0.37% | — |
| 7 July | 0.37% | — |
| 6 July | 0.36% | — |
| 3 July | 0.37% | — |
| 2 July | 0.38% | — |
| 1 July | 0.38% | — |
Orthocell Limited (OCC) Short Interest Summary
Orthocell Limited (OCC) currently has 0.39% of its shares sold short (1.1 million shares, worth approximately $795K), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes OCC the #338 most shorted stock on the ASX most shorted list. Short interest in OCC is up 0.03% over the past week and down 0.07% over the past month. OCC is part of the Health Care sector on the ASX.
Recent OCC Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 0.39% | 1.1M | $0.85 |
| 10 July 2026 | 0.38% | 1.0M | $0.85 |
| 9 July 2026 | 0.38% | 1.0M | $0.83 |
| 8 July 2026 | 0.37% | 1.0M | $0.85 |
| 7 July 2026 | 0.37% | 1.0M | $0.87 |
| 6 July 2026 | 0.36% | 1.0M | $0.83 |
| 3 July 2026 | 0.37% | 1.0M | $0.75 |
| 2 July 2026 | 0.38% | 1.0M | $0.72 |
| 1 July 2026 | 0.38% | 1.0M | $0.72 |
| 30 June 2026 | 0.39% | 1.1M | $0.73 |
OCC Short Selling — Frequently Asked Questions
What is Orthocell Limited (OCC)'s current short interest?
Orthocell Limited (OCC) currently has a short interest of 0.39% of total shares outstanding. This means 0.39% of OCC's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is OCC heavily shorted on the ASX?
OCC has a relatively low short interest of 0.39%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for OCC investors?
Short interest in OCC shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.39%, OCC's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this OCC short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for OCC.